HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Di Ianni, M. Articles by Tabilio, A. Search for Related Content PubMed PubMed Citation Articles by Di Ianni, M. Articles by Tabilio, A.

In Vivo Demethylation of a MoMuLV Retroviral Vector Expressing the Herpes Simplex Thymidine Kinase Suicide Gene by 5' Azacytidine

^a Haematology and Clinical Immunology and
^b Pathology Sections, Department of Clinical and Experimental Medicine, Perugia University, Perugia, Italy

Key Words. 5' Azacytidine • Retroviral vector • SCID mice • lacZ

Antonio Tabilio, M.D., Haematology and Clinical Immunology Section, Department of Clinical and Experimental Medicine, Perugia University, Policlinico Monteluce, V. le Brunamonti, 06122 Perugia, Italy. Telephone: 39-075-5783990; Fax: 39-075-5726449; e-mail: medemat{at}unipg.it

We constructed a functional MoMuLV-based bicistronic retroviral vector encoding the herpes simplex virus type I thymidine kinase gene, which induces sensitivity to the prodrug ganciclovir (gcv), and the reporter ß-galactosidase gene (MFG-tk-IRES-lacZ). The U937 histiocytic cell line was transduced with this vector, and a clone (VB71) with high-level transgene expression was selected. Severe combined immunodeficient (SCID) mice were injected with VB71 cells to evaluate the role of long terminal repeat methylation in transgene silencing in vivo and to see whether 5-azacytidine (5' aza-C) demethylating agent prevented it.

We found 5' aza-C maintained gene expression at high level in vitro. In vivo, time to tumor onset was significantly longer in SCID mice receiving the VB71 cells, 5' aza-C, and gcv compared with animals treated with either 5' aza-C or gcv alone. The number of injected tumor cells influences tumor onset time and the efficacy of 5' aza-C and gcv treatment. The standard gcv treatment schedule (10 mg/kg from d + 1 until the onset of tumor) controlled tumor onset better than short-term treatment with high doses. In conclusion, the results extend our previous findings that transgene methylation in vivo may be prevented with an appropriate schedule of 5' aza-C and gcv.